August 25, 2020
Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, has completed its upsized initial public offering of 6,151,162 shares of common stock, which includes the full exercise of the underwriters’ option to purchase an additional 802,325 shares of common stock, at a price to the public of US$24 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Harmony, are expected to be US$147.6 million. All of the shares are being offered by Harmony. The shares began trading on the Nasdaq Global Market under the ticker symbol “HRMY” on August 19, 2020.
Latham & Watkins LLP represented Harmony Biosciences Holdings, Inc. in the offering with a corporate team led by Chicago partners Christopher Lueking and Mark Gerstein, with associates Jonathan Sarna, Scott Westhoff, KC Sands, and Ryan Hudson. Advice was also provided on securities law matters by Washington, D.C. partners Alex Cohen and Paul Dudek; on benefits and compensation matters by Los Angeles/Orange County partner Michelle Carpenter, with associate Jordan David; on public company representation matters by Washington, D.C. associates Will Hackett and Charlie Guinn; on healthcare and life sciences matters by Washington, D.C. partner Elizabeth Richards and Silicon Valley/San Diego partner Chris Hazuka, with counsel Betty Pang and associates Barrett Tenbarge and Rob Yeh; and on tax matters by Chicago partner Rene de Vera.